Based on the unique mechanism of action of TTFields, multiple clinical studies investigating the efficacy and safety of TTFields in a range of cancer types have been initiated, including1-8:
| Clinic Trial | Phase | Status | Estimated Enrollment | Estimated Primary Completion Date |
|---|---|---|---|---|
A phase III study of TTFields following stereotactic radiosurgery (SRS) for the treatment of 1-10 brain metastases from non-small cell lung cancer (NSCLC) more… |
Phase III | Recruiting | 270 | September 2022 |
A phase III study of TTFields concomitant with standard of care therapies for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure more… |
Phase III | Active, not recruiting | 276 | September 2023 |
A phase III study of TTFields concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer more… |
Phase III | Active, not recruiting | 540 | September 2023 |
A phase III study of TTFields concomitant with gemcitabine and nab-paclitaxel as the front-line treatment of unresectable, locally advanced pancreatic adenocarcinoma more… |
Phase III | Recruiting | 556 | September 2024 |
A phase III study of TTFields concomitant with radiotherapy and temozolomide for the treatment of newly diagnosed glioblastoma (GBM) more… |
Phase III | Recruiting | 950 | August 2024 |
A phase II study of TTFields concomitant with XELOX as the first-line treatment of unresectable, locally advanced or metastatic gastroesophageal junction (GEJ) or gastric (GC) adenocarcinoma more… |
Phase II | Active, not recruiting | 28 | September 2021 |
A phase II study of TTFields delivered through high intensity arrays for the treatment of recurrent glioblastoma (GBM) more… |
Phase II | Recruiting | 25 | January 2022 |
A phase II study of TTFields concomitant with pembrolizumab as the first-line treatment of advanced or metastatic intrathoracic, PD-L1 positive non-small cell lung cancer (NSCLC) more… |
Phase II | Recruiting | 66 | July 2024 |
References:
- National Institutes of Health U.S National Library of Medicine. METIS trial. Available at: https://clinicaltrials.gov/ct2/show/NCT02831959. Accessed 2 August, 2022.
- National Institutes of Health U.S National Library of Medicine. LUNAR trial. Available at: https://clinicaltrials.gov/ct2/show/NCT02973789. Accessed 2 August, 2022.
- National Institutes of Health U.S National Library of Medicine. ENGOT-ov50/GOG-3029/INNOVATE-3 trial. Available at: https://clinicaltrials.gov/ct2/show/NCT03940196. Accessed 2 August, 2022.
- National Institutes of Health U.S National Library of Medicine. PANOVA-3 trial. Available at: https://clinicaltrials.gov/ct2/show/NCT03377491. Accessed 2 August, 2022.
- National Institutes of Health U.S National Library of Medicine. TRIDENT trial. Available at: https://clinicaltrials.gov/ct2/show/NCT04471844. Accessed 2 August, 2022.
- National Institutes of Health U.S National Library of Medicine. EF-31/ZL-8301-001 trial. Available at: https://clinicaltrials.gov/ct2/show/NCT04281576. Accessed 2 August, 2022.
- National Institutes of Health U.S National Library of Medicine. EF-33 trial. Available at: https://clinicaltrials.gov/ct2/show/NCT04492163. Accessed 2 August, 2022.
- National Institutes of Health U.S National Library of Medicine. KEYNOTE B36 trial. Available at: https://clinicaltrials.gov/ct2/show/NCT04892472. Accessed 2 August, 2022.